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Fibrocyte measurement in peripheral blood
correlates with number of cultured mature
fibrocytes in vitro and is a potential
biomarker for interstitial lung disease in
Rheumatoid Arthritis
Søren Andreas Just1*, Hanne Lindegaard1, Eva Kildall Hejbøl2, Jesper Rømhild Davidsen3, Niels Bjerring4,
Søren Werner Karlskov Hansen5, Henrik Daa Schrøder2, Inger Marie Jensen Hansen6, Torben Barington7,8
and Christian Nielsen7
Abstract
Background: Interstitial lung disease (ILD) can be a severe extra-articular disease manifestation in Rheumatoid
Arthritis (RA). A potential role of fibrocytes in RA associated ILD (RA-ILD) has not previously been described. We
present a modified faster method for measuring circulating fibrocytes, without intracellular staining. The results are
compared to the traditional culture method, where the number of monocytes that differentiate into mature fibrocytes
in vitro are counted. The results are following compared to disease activity in patients with severe asthma, ILD, RA
(without diagnosed ILD) and RA with verified ILD (RA-ILD).
Method: CD45+ CD34+ CD11b+ (7-AAD− CD3− CD19− CD294−) cells were isolated by cell sorting and stained for pro-
collagen type 1. Thirty-nine patients (10 RA, 9 ILD and 10 with severe asthma, 10 with RA-ILD) and 10 healthy controls
(HC) were included. Current medication, disease activity, pulmonary function test and radiographic data were collected.
Circulating fibrocytes were quantified by flow cytometry. Peripheral blood mononuclear cells were isolated and cultured
for 5 days and the numbers of mature fibrocytes were counted.
Results: 90.2% (mean, SD = 1.5%) of the sorted cells were pro-collagen type 1 positive and thereby fulfilled the criteria
for being circulating fibrocytes. The ILD and RA-ILD groups had increased levels of circulating fibrocytes compared to
HC (p < 0.05). Levels of circulating fibrocytes correlated overall to number of monocytes that subsequently in vitro
differentiated to mature fibrocytes (r = 0.81, p < 0.001). RA patients with pathologically reduced diffusion capacity for
carbon monoxide adjusted for hemoglobin (DLCOc) in both the RA and in the combined RA + RA-ILD group, had
significantly higher levels of both circulating and number of cultured mature fibrocytes (both p < 0.05). In both groups,
the level of circulating fibrocytes and number of mature fibrocytes in culture also correlated to a reduction in DLCOc
(r = −0.61 an r = −0.58 both p < 0.05).
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Conclusions: We presented a fast and valid method for measuring circulating fibrocytes using flow cytometry on lysed
peripheral blood. Further, we showed for the first time, that the level of circulating fibrocytes correlated with the
number of peripheral blood mononuclear cells, that differentiated into mature fibrocytes in vitro. Reduced DLCOc
was correlated with high levels of circulating and mature fibrocytes in RA, which have not been reported previously. In
such, this study suggests that fibrocytes may exhibit an important role in the pathogenesis of RA-ILD, which requires
further clarification in future studies.
Trial registration: ClinicalTrials.gov:NCT02711657, registered 13/3–2016, retrospectively registered.
Keywords: Rheumatoid arthritis, Interstitial lung disease, Fibrocytes
Background
Interstitial lung diseases (ILDs) are a heterogeneous group
of Diffuse Parenchymal Lung Diseases (DPLD) that may
be idiopathic or secondary to a known etiology. In
Rheumatoid Arthritis (RA) 10–20% of all patients present
with pulmonary manifestations as part of RA associated
ILD (RA-ILD). RA-ILD has limited treatment options and
is attributable to nearly 10% of deaths in RA patients [1].
The precursor cell type for the lung myofibroblasts,
which in ILD are persistently activated and produce
excessive amounts of extracellular matrix fibrosis com-
ponents, has yet to be identified [2, 3]. Bone marrow-
derived cells, called fibrocytes, are believed to originate
from a monocyte-derived precursor, and fibrocyte levels
are increased both in peripheral blood and in the af-
fected tissue in fibrotic diseases [4]. Fibrocytes are de-
fined as cells expressing both hematopoietic (e.g. CD45,
CD34), myeloid (e.g. CD11b) and stromal markers (e.g.
pro-collagen type 1) [5]. Fibrocytes migrate to sites of in-
flammation or tissue damage and transform into spindle
shaped fibroblast-like cells classified as the mature fibro-
cyte [2]. The transformation is controlled by T-cell inter-
action and a wide range of inducing or inhibiting
chemokines and cytokines [6, 7]. The mature fibrocytes
secrete extracellular matrix fibrosis components like col-
lagen I/III and fibronectin, and the cells are naturally in-
volved in both tissue repair and fibrosis [4]. Notably,
collagen is a central component in fibrosis matrix during
pathophysiological conditions. Further, elevated fibrocyte
levels both circulating and in lung biopsies have been re-
ported in patients with idiopathic pulmonary fibrosis
(IPF) [8–10]. In murine models, development of lung fi-
brosis is directly associated with the influx of fibrocytes
to the lung [2, 11]. Moreover, it has been demonstrated
that adaptive infusion of fibrocytes worsened disease
activity in murine disease models of lung and kidney
fibrosis and also in collagen induced arthritis [12]. Add-
itionally, in patients with severe asthma, disease activity
has been found to correlate with the levels of circulating
and intrapulmonary fibrocytes [13–15]. In summary,
current knowledge indicates that circulating fibrocytes
could be one of the precursor cells of the lung
fibroblasts and myofibroblasts with a central role in fi-
brotic ILD pathogenesis. However, whether fibrocytes
are involved in RA-ILD is currently unknown.
The used method for culturing mature fibrocytes from
isolated peripheral blood mononuclear cells (PBMC),
using serum free medium (SFM) has previously been vali-
dated and used in several studies [7, 16–18]. Culturing is
often done with an agent stimulating fibrocyte differenti-
ation, in particular interleukin 4 (IL-4). IL-4 is produced
by T helper cell type 2 (Th2) cells. Elevated Th2 cell levels
are observed in early RA (blood and synovial fluid), IPF
(blood and lung), and asthma (blood and lung) [19–21].
Circulating fibrocytes have traditionally been identified
among PBMCs by measurement of expression levels of
extracellular hematopoietic cell surface markers (cluster
of differentiation (CD); typically, CD45 and/or CD34)
combined with cell permeabilization and labeling for
intracellular mesenchymal markers (e.g. collagen type 1/
pro-collagen type 1/vimentin) [22]. However, this meth-
odology is time consuming and expensive. Also, it con-
tains several washing steps to isolate PBMCs, uses cell
permeabilization, fails to provide absolute fibrocyte con-
centration and results in non-viable cells making it im-
possible to analyze their differentiative capacity [13].
Recently, a method for measuring fibrocytes in periph-
eral blood by flow cytometry using only cell surface
markers followed by red blood cell lysis has been intro-
duced and validated [13]. This method enumerates
CD45+ CD34+ CD11b+ (CD3− CD19− CD20− CD294−
CD115− CD16− 7AAD−) cells, and the validation experi-
ments by Bianchetti et al. found the cells to contain
intracellular collagen when stimulated with endothelin 1
(ET-1), and thereby fulfilling the definition for being
fibrocytes [13].
Mature tissue resident spindle shaped fibrocytes and circu-
lating fibrocytes are two distinct entities. Thus, it could be in-
formative to measure both concomitantly. We hypothesized
that levels of circulating fibrocytes can be measured, using
surface markers on lysed blood cells only, and that these
levels correlate with levels of mature cultured fibrocytes.
The aim of this study was to establish a fast and reli-
able method for quantification of circulating fibrocytes
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and evaluate whether the fibrocyte levels correlated to
disease severity in patients with fibrotic ILDs (IPF and
non-specific interstitial pneumonitis (NSIP)), severe
asthma, RA (not diagnosed with ILD) and RA with veri-
fied ILD (RA-ILD).
Methods
Study design, setting and study cohort
We performed a single center case-based cross-sectional
study at Odense University Hospital (OUH) with inclu-
sion of 10 blood donors from the Department of Clinical
Immunology, 10 patients receiving omalizumab (Xolair,
Novartis) for severe asthma, 9 patients with fibrotic ILD
(IPF or NSIP) from the Department of Respiratory
Medicine, 10 patients with RA and 10 RA patients with
verified RA-ILD from the Department of Rheumatology.
All study subjects were included as part of their regular
follow-up. RA patients fulfilled the EULAR/ACR 2010
criteria for RA and Disease Activity Score in 28 joints
combined with CRP value (DAS28CRP) were recorded.
Further Rheumatoid factor (RF) and cyclic citrullinated
peptide antibody (anti-CCP) value was recorded. Data
on peak flow, Asthma Control Test (ACT) score, and
pulmonary function tests (PFT) were recorded on severe
asthma, ILD and RA-ILD patients. Diagnoses regarding
severe asthma, ILD and RA-ILD were confirmed on prior
multi-disciplinary discussion conferences with presence of
pulmonologists, rheumatologists, radiologists and pathol-
ogists. No criteria regarding disease duration or disease
activity were set for enrollment.
For the establishment of the method, blood from
healthy blood donors was used, with only information
regarding age and sex registered.
Flow cytometry
Twenty milliliter peripheral blood was collected in ethyl-
enediaminetetraacetic acid (EDTA). Hereafter, a slightly
modified method of Bianchetti et al. was used [13].
Briefly, 100 μL of whole blood were transferred to a Tru-
count absolute counting tube (BD Bioscience, San Jose,
USA) and labelled with the following monoclonal anti-
bodies: CD45-V500C (dose 5 μL Clone 2D1), CD34-PE
(dose 5 μL Clone 581), CD11b-Pacific Blue (dose 5 μL
Clone ICRF44), Via-Probe (7-AAD) (dose 2 μL), CD3-
PE-Cy5 (dose 2.5 μL Clone HIT3a), CD19-PerCP-
Cy5.5(dose 2.5 μL Clone HIB19), CD294-PerCP-Cy5.5
(dose 2.5 μL Clone BM16) (All BD Bioscience, San Jose,
USA), all titrated for no-wash staining. After 20 min of
dark incubation at room temperature, 2 ml of High Yield
Lyse Solution (Thermo Fisher Scientific, Waltham, USA)
were added for red cell lysis and tubes were stored for
10 min in the dark. Immediately hereafter, the sample
was analyzed using a BD FACSCanto II (4 laser) flow
cytometer, which was adjusted using BD Cytometer
Setup and Tracking Beads. Compensation settings were
performed using BD CompBead antibody-capturing par-
ticles (BD Bioscience, San Jose, USA) and the automatic
compensation setup tool in the BD FACS Diva software.
Fluorescence-minus-one controls were used for accurate
definition of cells that had fluorescence above back-
ground levels. Relevant isotype controls for CD45-
V500C (dose 5 μL Clone X40), CD34-PE (dose 5 μL
Clone MOPC-21) and CD11b-Pacific Blue (dose 5 μL
Clone MOPC-21) (all BD Bioscience, San Jose, USA)
were used in the initial setup and frequently between
tests. Data was acquired using BD FACSDiva software
(BD Bioscience, San Jose, USA) and analyzed on FlowJo
version 10 (Treestar, Ashland, USA). The gating strategy
is described in Fig. 1.
For validation, coefficient of variation (CV%) was mea-
sured using blood from a healthy individual by measur-
ing six independently prepared samples from the same
blood tube. Further, CV% was assessed by measuring on
the same stained sample 5 times. To test the effect of
storing the blood sample for 24 h at room temperature
on the fibrocyte count measurement, 4 samples were
prepared from a stored blood tube and stained. Further,
the effect of storing for 24 h was assessed for the stained
and lysed samples. In the following the measured popu-
lation of CD45+ CD34+ CD11b+ (7-AAD− CD3− CD19−
CD294−) cells will be referred to as CD45+ CD34+
CD11b+ cells.
CD45+ CD34+ CD11b+ cells were further tested for
the expression of the following surface markers: CXCR4-
APC (dose 5 μL Clone 12G5), CD115-Alexa Fluor 647
(dose 5 μL Clone 94D21E4), CD16-FITC (dose 7.5 μL
Clone B73.1) and CD20-PerCP-Cy5.5 (dose 1.25 μL
Clone 2H7) (all BD Bioscience, San Jose, USA).
Culturing mature fibrocytes
PBMCs were cultured as previously described [16]. Briefly,
PBMCs were isolated from 20 ml of peripheral EDTA
blood using Lymphoprep (StemCell, Grenoble, France) ac-
cording to manufacturer’s instructions. The culture media
consisted of the following products for the production of
a total of 50 ml: 47 ml of FibroLife (LifeLine Cell Technol-
ogy, Frederick, USA), 0.5 ml of HEPES (10 mM), 0.5 ml
Non-essential amino acids (NEAA), 0.5 ml of Sodium
pyruvate (1 mM), 0.5 ml of Glutamine (2 mM), 0.5 ml of
Pen-Strep (Penicillin (100 U/ml) and Streptomycin
(100 μg/ml)), and 0.5 ml of ITFS-3 (All Sigma-Aldrich, St.
Louis, USA) and 5 ng/ml IL-4 (CellSystems, Troisdorf,
Germany). A monocyte, lymphocyte, granulocyte and eo-
sinophil count was performed using PBMCs (Sysmex,
Kobe, Japan). Hereafter cells were adjusted to 1 × 106
cells/ml culture media. Flat bottom 24-well plates (Nunc,
Thermo Fisher Scientific) were used in combination with
glass coverslips (Thermo Fisher Scientific) placed at the
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bottom of each well. Ten wells were each filled with
200 μl of cell suspension and supplemented with a further
500 μl of culture media. The plate was placed in a humidi-
fied incubator (37 °C, 5% CO2) for 5 days. Non-adherent
cells (e.g. T and B-cells) were discarded and the remaining
cells were harvested, by removing the coverslips, washing
twice in PBS and drying it. Before staining the coverslips
were mounted on glass slides.
Quantification of fibrocytes
Two coverslips were Giemsa stained, scanned using
NanoZoomer 2.0-HT (Hamamatsu, Hamamatsu, Japan)
and cells were counted using NDPIviewer (Hamamatsu).
Mature fibrocytes were defined as spindle shaped cells
with a minimum length of 40 μm (See Fig. 2a). For posi-
tive cell counting, eight fields on each of two separate
coverslips were randomly selected and counted for fibro-
cytes. The range of counted cells per person was from 7
to 148 fibrocytes. From this number, an estimate of the
total number of fibrocytes in the well was calculated and
the fibrocyte counts from two different wells from the
same patient were averaged to give the fraction of
PBMCs that differentiated to fibrocytes. By using the dif-
ferential count performed on the isolated PBMCs before
culture, the number of fibrocytes per 105 monocytes
added to the well was calculated. For validation of the
fibrocyte culture method, the number of cells counted
on the two different wells from the same patient was
correlated. The stained samples from the RA-ILD pa-
tients were counted manually with a microscope, using
the same method as described above.
Immunocytochemistry
Immunocytochemistry was performed on cultured fibro-
cytes on coverslips. Staining was performed using the
PowerVision+/DAB detection system. The primary anti-
body used was Anti-Procollagen Type 1 antibody (clone
2Q576, Abcam, Cambridge, UK) at a dilution of 1:150.
Fig. 1 Gating strategy for quantification of fibrocytes using lysed peripheral blood. Representative flow cytometry analysis showing the gating strategy.
Population was initially gated on the basis of the forward side scatter characteristics and debris were eliminated, then lymphocyte and monocytes were
selected, the CD45+ cells were gated in the plot “CD45-V500” versus forward scatter. Hereafter unwanted cells as B-Cells (CD19+), T-Cells (CD3+), basophils
and eosinophils (CD294+) and dead cells (7AAD+) were removed using a PerCP-Cy5-5A dump channel. Finally, the CD45+ CD34+ Cd11b+ fibrocyte
population was measured in the “CD11b-Pacific blue versus CD34-PE” plot. Fluoroscence minus one (FMO) controls are shown at the bottom
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Fluorescence activated cell sorting (FACS)
Cell sorting was done to determine whether the used anti-
body panel identified cells that express pro-collagen type 1.
Twenty milliliter of peripheral blood were drawn from two
RA and two asthma patients and PBMCs were isolated.
Firstly, CD34+ cells were isolated using positive selection
magnetic beads (StemCell, Grenoble, France). The process
was done according to manufacturer’s instructions, with
one modification. The RosettaSep cocktail was not added
to avoid removing CD16+ cells, as a fraction of fibrocytes
has been reported be CD16+ (discussed later) [23].
The isolated CD34+ cells were diluted in Hanks bal-
anced salt solution, with human albumin and EDTA
(0.5 mg of HSA/ml, 2 mM EDTA, Sigma-Aldrich, St.
Louis, USA). The cells were stained for CD34 (dose
20 μL clone 8G12) and CD11b, CD45 CD3, CD19,
CRTH2 and with 7 AAD (same dose, clones and firm as
described under Flow cytometry). Cells were aseptically
sorted on a BD FACSAria cytometer (BD Bioscience,
San Jose, USA) using the BD FACSDiva software and the
gating strategy as described in Fig. 1. The CD45+ CD34+
cells were divided into CD11b+ and CD11b− cells and
placed in flat bottomed wells with a glass coverslip
placed at the bottom. Fibrocytes were matured wit IL-4
as above, but only cultured for 2 days. Purity of sorted
cells was evaluated by flow cytometry and the CD34
Fig. 2 Mature and circulating fibrocytes. Appearance of fibrocytes in a PBMCs cultured for 5 days in serum free medium; giemsa stain. b Cultured
PBMCs. The arrow points at a pro-collagen type 1 positive cell. c Pro-collagen type 1 positive CD45+CD34+CD11b+ sorted cell from an RA patient.
d Cultured fibroblast used as positive control for the pro-collagen type 1 stain. e IgG isotype control. The scale bar represents 100 μm
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isolation negative selection rest product. Further infor-
mation on flow cytometry, cell culture and cell sorting
procedure, is presented in Additional file 1: Table S1.
Disease activity
Disease activity, current medication and PFTs results were
collected from the patients’ medical records. C-reactive
protein (CRP), hemoglobin, leukocyte differential count,
creatinine and liver function tests were measured at time
of inclusion (+/− 1 day) as part of routine monitoring of
disease activity. Elevated levels were defined as leucocytes
>10 × 109/L, neutrophils >7 × 109/L, lymphocytes > 4 × 109/
L, monocytes >0.7 × 109/L, eosinophils > 0.5 × 109/L,
basophils >0.2 × 109/L and for CRP >10 mg/L.
Thoracic imaging data (i.e. chest X-ray and/or high-
resolution computed tomography (HRCT)) performed
within 2 years from the date of obtaining blood test was
registered. A pathological hemoglobin corrected diffu-
sion capacity for carbon monoxide (DLCOc) was defined
as below 80% of predicted.
Statistics
Categorical variables were presented as numbers and
percentages, and continuous variables as medians with
25th -75th percentile values (P25-P75). When two groups
were compared Fisher’s exact test for categorical data and
Mann-Whitney U test for continuous data was used. Cor-
relations were examined with Spearman’s correlation.
Comparisons between multiple groups were done with
Kruskal-Wallis test followed by Dunn’s post hoc test. Statis-
tical significance was identified as p-value <0.05. Data were
analyzed on Stata version 14.0 (StataCorp, Texas, USA).
Results
Circulating Fibrocytes
The purity of the sorted CD45+ CD34+ CD11b+ cells
was 86%. At average 90.2% (SD ±1.5%) of the CD45+
CD34+ CD11b+ cells were pro-collagen type 1 positive
compared to only 6.3% (SD ±4.6%) of the corresponding
CD45+ CD34+ CD11b− cells were procollagen type 1
positive (Fig. 2). The CD45+ CD34+ CD11b+ cell popula-
tion thereby fulfilled the criteria of circulating fibrocytes.
The frequencies of CD20, CD115, CXCR4 and CD16
expression on the CD45+ CD34+ CD11b+ cell population
were 1, 3, 75, and 45% respectively (Additional file 1:
Table S2).
Repeated measurement of the sample taken the same
day from a healthy donor gave a coefficient of variation
(CV%) on 9.1%, with a median of 1.4 fibrocytes/μL (P25-
P75 1.2–1.5). Repeated measurement on the same sample
after 24 h at room temperature gave a CV% of 9.4% with a
median of 1.4 fibrocytes/μL (P25-P75 1.2–1.6). No statisti-
cally significant difference between median fibrocyte
values on the day of sample collection and after 24-h stor-
age was found (P = 0.8). The lysed and stained samples
from the day of sample collection were stored for 24 h in
a refrigerator and re-measured resulting in a CV% of 14%
with a median of 1.2 fibrocytes/μL (P25-P75 1.1–1.4),
without a significant day to day difference (P = 0.3).
Cultured fibrocytes
The mean CV% among all patients and healthy controls
of the number of mature fibrocytes between the two
coverslips was 14.4%. This was based on 35 double enu-
merations, the RA-ILD group was not included, and
further missing 4 double enumerations due to 3 patients
(2 severe asthma and 1 ILD), for which culture failed
and two asthma patients where only one coverslip could
be counted. Median numbers of counted mature fibro-
cytes are presented in Table 1. All groups except the ILD
group (p = 0.08) had significantly increased levels of ma-
ture fibrocytes compared to HC, while there were no
significant differences in levels between the different
patient groups (See Fig. 3b).
Correlation between circulating and cultured fibrocytes
Baseline demographic and clinical characteristics of
study participants are presented in Table 2.
Age and sex were not correlated to the number of
CD45+ CD34+CD11b+ cells or number of cultured fibro-
cytes in the healthy individuals (p = 0.9 and p = 0.3
respectively). When including the disease groups (total
n = 49) there is a correlation to age for both circulating
Table 1 Level of circulating and mature fibrocytes according to disease group
Control RA Severe asthma IPF/NSIP RA-ILD
n = 10 n = 10 n = 10 n = 5/n = 4 n = 10
Flow cytometry
2003CD45+CD34+CD11b+ cells/μL
median (P25-P75)
1.69
(0.94–2.89)
3.84
(2.52–6.25)
4.88
(3.44–6.16)
6.13
(3.58–7.93)
6.45
(5.89–9.44)
Cultured mononuclear cells
Fibrocytes/105 monocytes
median (P25-P75)
887
(331–1590)
4140
(3069–5557)
4634
(3213–6881)
3897
(2570–5809)
6266
(3946–7437)
Cells presented in counted numbers and as medians with 25th- and 75th percentiles in brackets. Culture of mononuclear cells failed from 4 patient
samples (2 Severe Asthma, 1 ILD, 1 RA-ILD)
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fibrocytes and number of cultured fibrocytes (r = 0.40
p = 0.006 and r = 0.39 p = 0.01 respectively).
Patients with smoking status current or former had
higher levels of CD45+ CD34+CD11b+ cells, compared
to never smokers (16 versus 19 patients, p = 0.01). Num-
ber of cultured fibrocytes was not different (p = 0.09).
Figure 3a and b illustrates the CD45+ CD34+CD11b+
cell and mature fibrocyte levels in patients according to
disease category. ILD and RA-ILD patients had signifi-
cantly higher levels of CD45+ CD34+CD11b+ cells
compared to healthy controls (HC) (Fig. 3a, p=0.01 and
p = 0.001 respectively). While there was no significant
difference for RA or the severe asthma group compared
to HC (p = 0.26 and p = 0.06 respectively). Further, there
were no significant differences between the different
disease categories (e.g. RA vs. RA-ILD; p = 0.14).
RA, severe asthma and RA-ILD all had higher levels of
mature fibrocytes compared to HC (Fig. 3b, all p < 0.05).
No significant difference was seen between HC and ILD
(p = 0.08) or between the different disease categories.
Further, there was a significant linear correlation be-
tween measured CD45+ CD34+ CD11b+ cells and the
number of counted mature fibrocytes per 105 added
monocytes in culture was r = 0.81, p < 0.001 (Fig. 3c).
Correlation between CD45+CD34+CD11b− and number
of the cultured mature fibrocytes was insignificant
(r = 0.17; p = 0.31).
Within the individual disease groups, levels of CD45+
CD34+CD11b+ cells and mature fibrocytes correlated
significantly within HC, RA, ILD and RA-ILD but not in
patients with severe asthma (HC (r = 0.76, p = 0.01), RA
(r = 0.70 p = 0.02), severe asthma (r = 0.56, p = 0.15),
ILD (r = 0.83, p = 0.01), RA-ILD (r = 0.85, p = 0.003).
Association with disease activity
In the combined group of RA, severe asthma, ILD and
RA-ILD patients, the level of cultured fibrocytes and
CD45+ CD34+CD11b+ cells was significantly higher in
the patients with normal C-reactive protein (CRP)
(<10 mg/L) than in patients with elevated CRP (both
p = 0.001). Median CRP in the patients with normal
CRP was 2.7 mg/L (P25-P75: 1.9–4.7) and in the patients
with elevated CRP 28 mg/L (P25-P75: 16–43). CD45+
CD34+CD11b+ cells and level of mature fibrocytes was
significantly increased in the group with elevated mono-
cytes (both P = 0.03). Monocyte levels was correlated to
CD45+ CD34+CD11b+ cell levels (r = 0.3 p = 0.04), but
not with number of mature fibrocytes (r = 0.24
p = 0.11).
In the severe asthma group the level of CD45+ CD34
+CD11b+ cells correlated to decline in forced expiratory
volume in 1 s (FEV1) (r = −0.68 p = 0.03) (Fig. 4). Fibro-
cyte levels did not correlate to Asthma Control Test
Score (p = 0.9).
In the RA patients (combined RA and RA-ILD group),
disease activity (DAS28CRP) was not correlated with
level of CD45+ CD34+CD11b+ cells or cultured mature
fibrocytes (r = −0.17, p = 0.47 and r = −0.31, p = 0.20 re-
spectively). Further, RA patients not in remission
(DAS28CRP > 2.6) did not have increased levels of
CD45+ CD34+CD11b+ cells or number of fibrocytes in
culture (p = 0.9 and p = 0.8). The same pattern appeared
when comparing patients with moderate to high disease
activity (DAS28CRP > 3.2) versus the rest (data not
shown). Anti-cyclic citrullinated protein antibody (Anti-
CCP) or IgM-Rheumatoid factor (RF) positivity did not
correlate to the level of CD45+ CD34+CD11b+ cells or
number of mature fibrocytes (all p > 0.2). Ninety percent
of patients in the RA-ILD group were both anti-CCP
and RF positive, the last solely RF positive. The RA-ILD
group were not older or had longer disease course com-
pared to the RA group (p = 0.15 and p = 0.57
respectively).
Based on a radiological pattern recognition on a high-
resolution computed tomography (HRCT) of the thorax
the RA-ILD patients included had the following ILD
Fig. 3 Levels of CD45+ CD34+ CD11b+ cells and number of mature fibrocytes after 5 days in culture. a Comparison of CD45+ CD34+ CD11b+ cell
levels. NS = not significant. b Comparison of number of mature fibrocytes after 5 days in culture. c Correlation between CD45+ CD34+ CD11b+
cells in blood measured by flow cytometry and number of mature fibrocytes after 5 days in culture
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subtypes: non-specific interstitial pneumonia (NSIP) = 4,
bronchiolitis obliterans (BO) = 3, hypersensitive pneu-
monitis (HP) = 2, usual interstitial pneumonia (UIP) = 1.
In addition, four of the RA-ILD patients had their diag-
nosis histological confirmed on basis of surgical lung
(n = 3) or bronchoscopic lung cryobiopsy (n = 1).
Prednisolone treated RA patients did not have higher
levels of either CD45+ CD34+CD11b+ cells or number of
mature fibrocytes, compared to non-prednisolone
treated (p = 0.5 and p = 0.2). 85% of RA patients had
erosive disease, although this group did not have higher
levels of fibrocytes (p = 0.4 and p = 0.3 respectively).
Methotrexate treated RA patients had a median of 4.4
CD45+ CD34+CD11b+ cells/μL and 3366 mature
fibrocytes/105 monocytes (n = 11) versus untreated with
6.2 CD45+ CD34+CD11b+ cells/μL and 6368 mature
fibrocytes/105 monocytes (p = 0.16 and p = 0.05
respectively).
All patients in the RA-ILD and ILD groups had patho-
logical reduced DLCOc and signs of interstitial lung dis-
ease and/or fibrosis on high resolution computed
tomography (HRCT). In the RA group not diagnosed
with ILD, 5/9 (55%) had reduced DLCOc which was as-
sociated with a 51% higher levels of circulating fibrocytes
and 52% higher count of mature fibrocytes, compared to
RA patients with normal DLCOc (both p = 0.02) (Fig. 5a
and b). In the combined RA and RA-ILD group the
same patterns were observed (Fig. 5cp=0.005 and
Table 2 Demographic and clinical characteristics of study participants
Control RA Asthma IPF/NSIP RA-ILD
n = 10 n = 10 n = 10 n = 5/n = 4 n = 10
Age, years, median (P25-P75) 56 (51–59) 58 (49–66) 50 (36–56) 75 (66–78) 70 (55–75)
Female sex, n (%) 4 (40) 7 (70) 3 (30) 4 (44) 6 (60)
Current/former/never smokers (%)1 NA 20/10/70 10/20/70 0/78/22 20/70/10
Blood sample results
Hemoglobin, mmol/L, median (P25-P75) 9.1 (8.8–9.5) 7.8 (7.2–8.8) 9.1 (8.7–9.7) 8.5 (7.8–8.9) 8.25 (8–8.5)
CRP, mg/L, median (P25-P75) NA 5.4 (2.7–16) 3.2 (1.8–4.7) 2.3 (2–4.4) 8 (1.9–11)
Leucocytes, 109/L, median (P25-P75) 5.3 (4.6–5.8) 6.8 (5.9–9.6) 8.5 (8.1–9.1) 9.6 (8.2–11) 11.5 (6.7–14.5)
Monocytes, 109/L, median (P25-P75) 0.5 (0.4–0.6) 0.6 (0.5–0.7) 0.6 (0.5–0.8) 0.8 (0.6–1.1) 0.8 (0.7–1.0)
Radiological signs compatible with interstitial
lung disease and/or lung fibrosis2
Chest X-ray (n/N) 0/0 1/7 0/6 9/9 6/10
High Resolution CT (n/N) 0/0 0/0 0/7 9/9 10/10
Pulmonary Function Test
Lungfunction performed (n/N) 0/0 10/10 10/10 3 9/9 10/10 4
FVC (% predicted), median (P25-P75) NA 108 (103–16) 84 (70–99) 78 (66–90) NA
TLC (% predicted), median (P25-P75) NA 99 (94–103) NA 83 (64–93) NA
FEV1 (% predicted), median (P25-P75) NA 103 (92–112) 71 (61–81) 78 (72–85) 70 (39–86)
DLCOc (% predicted),median (P25-P75) NA 79 (67–89)
5 NA 36 (31–37) 58 (46–73)
Asthma patients
GINA score (Average) 6 5
ACT score, median (P25-P75) 18.5 (16–20)
RA patients
Disease Duration (Years), median (P25-P75) 5.4 (2.4–17) 11.8 (1.4–33)
DAS28CRP, median (P25-P75) 2.75 (1.9–3.8) 3.4 (3–4.2)
Anti-CCP positive (%)/RF positive (%) 80/80 90/90
Erosive disease 60% 90%
No treatment (%)/DMARDs (%)/Biological treatment (%) 10/70/50 0/80/50
P25-P75, percentile 25th - percentile 75th; NA = not available; CRP, C-reactive protein; HRCT, High Resolution Computerized Tomography; FVC, Forced Ventilatory Capacity;
TLC, Total Lung Capacity; FEV1, Forced Expiratory Volume in 1 s; DLCOc, Diffusion capacity of the Lung for Carbon monoxide corrected for hemoglobin level, GINA, Global
Initiative for Asthma; ACT, Asthma Control Test Score; DAS28CRP, Disease Activity Score 28 joints combined with CRP value; CCP, cyclic citrullinated peptide; RF, rheumatoid
factor; DMARD, Disease Modifying Anti Rheumatic Drugs. 1) Current or former smokers; 2) More recent than 2 years; 3) Standard Asthma lung-function test without body
plethysmography; 4) Most recent lungfunction tests on RA-ILD patients were without FVC and TLC, therefore not stated. 5) One patient without DLCOc value; 6) All patients
in anti-IgE treatment
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p = 0.0007 respectively). Among all RA patients the level
of circulating and mature fibrocytes correlated to decline
in DLCOc. (r=−0.61 p = 0.005 and r = −0.58, p = 0.01
respectively) (Fig. 5e and f).
Only one RA patient in the group not diagnosed with
ILD, had a reticular pattern on chest X-ray as an indica-
tive of potential fibrosis but without HRCT clarification.
The findings on chest X-ray versus without, did not cor-
relate with increased CD45+ CD34+CD11b+ level or
number of cultured fibrocytes (p = 0.3 and p = 0.11 re-
spectively). In the RA-ILD group all had radiological
signs of ILD on HRCT and 6/10 on chest x-ray. There
was no difference in fibrocyte levels in RA-ILD patients
with or without signs of ILD on chest X-ray (p = 0.2 and
p = 0.8 respectively).
Discussion
We have proven that peripheral blood CD45+CD34
+CD11b+ (7-AAD−CD3− CD19−CD294−) cells are circu-
lating fibrocytes, per definition as they express pro-
collagen type 1. For the first time, we show that the level
Fig. 4 Correlation of circulating fibrocytes with forced expiratory volume
in 1 s (FEV1), in asthma patients
Fig. 5 Fibrocytes and diffusion capacity. a Comparison of circulating fibrocytes between RA patients with high or low hemoglobin corrected diffusion
capacity. b Comparison of cultured mature fibrocytes between RA patients with high or low hemoglobin corrected diffusion capacity. c Comparison of
circulating fibrocytes between all RA patients, RA patients with ILD included, with high or low hemoglobin corrected diffusion capacity. d Comparison
of cultured mature fibrocytes between all RA patients, RA patients with ILD included, with high or low hemoglobin corrected diffusion
capacity. e Correlation of circulating fibrocytes with hemoglobin corrected diffusion capacity in all RA patients including RA-ILD patients. f Correlation
of cultured mature fibrocytes with hemoglobin corrected diffusion capacity in all RA patients, the RA patients with ILD included
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of circulating fibrocytes in peripheral blood correlates
with the number of monocytes that in vitro differentiate
into mature fibrocytes. Further, levels of circulating
fibrocytes were elevated in patients with ILD and RA-
ILD compared to HC. In patients with severe asthma,
the level of circulating fibrocytes correlated with reduc-
tion in FEV1. As far as we know, we report, for the first
time, that higher levels of both mature and circulating
fibrocytes in RA and RA-ILD patients are associated
with reduced DLCOc.
Previous studies have shown high levels of circulating
fibrocytes in IPF that correlated to disease severity and
in one study mortality [24, 25]. In accordance, we found
increased levels of circulating fibrocytes in the ILD
group, consisting of IPF and fibrotic NSIP patients, com-
pared to HC. All ILD patients had signs of lung fibrosis
on their chest X-rays compatible with their severely re-
duced DLCOc (median 36% of predicted). To better
understand the role of fibrocytes in the ILD group, stud-
ies of larger cohorts are required, including patients at
different disease stages. In this regard, the results from
the ongoing PROFILE multicenter prospective study on
ILD (NSIP and IPF) (Clinical trials NCT01134822), in
which the fibrocyte levels are studied prospectively ac-
cording to pulmonary function test and radiographic
data, are awaited.
Increased numbers of circulating fibrocytes have been
observed in murine RA models [4]. We found higher
levels of circulating fibrocytes in the RA-ILD group com-
pared to HC, not in the RA group not previously diag-
nosed with ILD. We found increased levels of in vitro
matured fibrocytes in both RA and RA-ILD patients com-
pared to HC. The levels of mature or circulating fibrocytes
were not increased in patients with elevated RA disease
activity. Thus we confirm the findings from a recent study
reporting that an elevated levels of circulating fibrocytes
(measured by traditional intracellular collagen staining) in
RA patients is unassociated to disease activity [26]. An
earlier publication from the same study group found that
the extent of fibrocyte activation in six RA patients, as
measured by phosphorylation of defined signaling effec-
tors, did correlate with RA disease activity [27].
The present study shows that the level of monocytes
differentiating to mature fibrocytes is elevated in RA and
RA-ILD, compared to HCs. Whereas fibrocyte levels has
previously been found elevated in synovial fluid in RA,
the level in RA-ILD patients has not been investigated
previously to our knowledge [26]. In the RA group, the
levels of circulating and mature fibrocytes were in-
creased in the group with pathological reduced DLCOc
(See Fig. 5a–d). To further investigate this relationship
in RA, prospective cohort studies following fibrocyte
levels and pulmonary function test combined with
HRCT data are warranted.
Overall, the levels of circulating or number of mature
fibrocytes were not increased in the subgroup of patients
with elevated CRP. In a previous in vitro study adding
increasing the doses of CRP did not inhibit fibrocyte
differentiation [28]. Elevated leukocyte levels were ac-
companied with increased levels of both circulating and
mature fibrocytes. This suggests that circulating fibro-
cytes cannot be used as a traditional inflammation
marker.
The traditional method for measuring circulating fibro-
cytes is to first isolate PBMCs and hereafter perform
permeabilization and fixation for intracellular staining [22].
This method involves several washing steps, is time con-
suming, costly and requires large volumes of venous blood,
which makes it difficult to use in daily clinical practice (see
Table 3 for comparison of the two methods). Further, a
measurement of the absolute fibrocyte concentration in
peripheral blood is not possible when using isolated
PBMCs. Therefore, the method introduced by Bianchetti et
al., where only surface markers were used and 100 μL of
venous blood was sufficient for quantitative fibrocyte mea-
surements, was a marked improvement. For a comparison
between the traditional method of measuring circulating
Table 3 Comparison of methods to measure circulating fibrocytes
in peripheral blood
Traditional New method
Material Peripheral blood Peripheral blood
Volume
needed
10 mL 100 μL
Processing Isolate PBMC
by density
centrifugation
(Ficoll-Paque)
Extracellular
antibodies added
Cell fixation and
permabilization
Intracellular
antibodies added
Add antibodies
and incubate.
Red blood cell lysis
solution added
Cell washing steps 8 0
Detection method Flow cytometry Flow cytometry
Fibrocyte
Concentration
Estimate percentage
of total PBMC or
per mL of blood
Absolute concentration
using beads
Processing
time
Over 3 h Under 1 h
Advantages Unused isolated PBMC
can be used for other
purposes (e.g. culture
or stored)
Fast and small
blood volume
Reduced cell loss due
to no washing steps
or permabilization
Reference [22] Method section or [13]
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fibrocytes and the method using only surface markers
please see Table 3.
In this study, we have simplified this method further
by omitting the antibodies against CD16, CD115 and
CD20 in the flow cytometric panel [13]. CD16 positive
cells should not in general be discarded in the flow cy-
tometry analysis, as mature fibrocytes can be CD16 posi-
tive, and cultures of CD14+CD16+ monocytes and CD14
+CD16− monocytes have been shown to differentiate to
the same level of mature fibrocytes [29, 30]. Further, iso-
lated CD34+CD16+ cells cultured with IL-4 established
spindle shaped morphology and collagen expression,
thereby fulfilling the criteria for being fibrocytes [23]. In
IPF, levels of peripheral blood monocytes with high ex-
pression of CD14+ CD16+ at baseline was associated
with a worse outcome in a prospective study, also sug-
gesting a role of CD16+ cells in the fibrotic disease [20].
A potential bias could here be contamination by CD16+
neutrophils, which was solved by the gate in the initial
FSC-SSC plot (See Fig. 1). CD115 and CD20 was omit-
ted as negative selection markers in our flow cytometry
analysis, as we found only 3 and 1% of the CD45+ CD34
+ CD11b+ cells, respectively, to be positive for these
markers. The presented flow cytometric method is quick
and stable with a low CV% of 9%, based on the very low
absolute fibrocyte count in healthy subjects (median of
1.4 fibrocytes/μL) and low data spread (P25-P75 of 1.2–
1.5 fibrocytes/μL). Further, the blood sample can be
stored for 24 h at room temperature without signifi-
cantly affecting the fibrocyte measurement, making the
method easy to adapt in daily clinical work.
Several findings in this study support that the fast and
stable flow cytometric method measures circulating
fibrocytes. First, after stimulation with IL-4 for 2 days
we found that the majority of CD45+ CD34+ CD11b+
cells were pro-collagen type 1 positive (90.2% (SD
±1.5%)), compared to only 6.3% (SD ±4.6%) of the corre-
sponding CD11b− cells. In agreement, a similar finding
by Bianchetti et al. showed that over 88% of sorted cells
from 6 asthma patients had collagen 1 expression, using
stimulation with endothelin 1 (ET-1) [13]. For further
evidence, we tested the CD45+CD34+CD11b+ population
for CXCR4 expression, which is used as a fibrocyte
marker in several studies [2, 14], and found a mean fre-
quency of 75% (SD ± 9%) of the cells expressed CXCR4.
Further, in our study the isolated procollagen type 1
positive CD45+CD34+CD11b+ cells resembled mono-
cytes in appearance and size, given further support as
fibrocytes are derived from a monocyte subset (See Fig.
2c). To further validate, the flow cytometry results of the
panel was compared with a distinct and well validated
method for estimating level of circulating cells differenti-
ating to fibrocytes [16, 31, 32]. This resulted in a signifi-
cant correlation (r = 0.81), between the measured level
in peripheral blood of CD45+CD34+CD11b+ cells and
the number of mature fibrocytes (Fig. 3c). This further
strengthens the validity of the presented flow cytometric
method.
Further, we included patients with severe asthma corre-
sponding to GINA level 5, and found that the level of cir-
culating fibrocytes correlated to FEV1 decline (r = −0.68
p = 0.03) (Fig. 4). This is in agreement with previous find-
ings of correlation between fibrocytes, defined predomin-
antly by intracellular collagen staining, and asthmatic
activity, further supporting the validity of the presented
flowcytometric panel [13–15]. In the case of severe
asthma, a potential explanation of the increased fibrocyte
levels could be due to an ongoing remodeling process in
the small airways which also leads to reduced ventilation
values on pulmonary function tests.
Several factors have been found to influence the in
vitro transformation of monocytes to mature fibrocytes
including CD4+ T-cell interaction, endothelin, serum
amyloid protein (SAP), TNF-α, thrombin, IL-4, IL-17
and IL-22. [6, 7]. IL-4 level is elevated in ILD and
asthma lung biopsies and in peripheral blood and syn-
ovial fluid in early RA [8, 15, 19, 26]. The method used
for in vitro culturing fibrocytes, where IL-4 is added,
could therefore potentially be a method to estimate
number of cells with potential to differentiate to mature
fibrocytes in the diseased organs. When culturing ma-
ture fibrocytes, adding IL-4 to the serum free media at
the concentration (5 ng/ml) used in the present study,
has previously been shown to result in a stimulation of
fibrocyte differentiation of around 200% compared to
serum free media without IL-4 [33].
A study limitation is that the sorted cells were not
stained without culture, or cultured for 5 days to investi-
gate whether the majority transformed to mature fibro-
cytes. Culturing was stopped after 2 days due to signs of
cell distress after the cell sorting procedure. Further, the
study population is small (n = 49), and although we did
find significant clinical correlations, this needs explor-
ation in larger cohorts. The culturing of mature fibro-
cytes was most difficult in the ILD group, with frequent
signs of cell distress on the stained cells. The majority of
ILD patients was elderly and had end stage lung disease,
which could have affected the in vitro cell viability. The
number of cells with potential to differentiate into ma-
ture fibrocytes could therefore be underestimated in this
group. Further, data on DLCOc in the asthma patients
was lacking, although this parameter is usually normal
or elevated in asthma [34]. Additionally, 6/49 patients
did not have recent radiographic data <2 year, and none
of the RA patients (not diagnosed with ILD) had under-
gone a HRCT. As HRCT is the first choice radiographic
modality when suspecting ILD, a potential drawback
could be that the study has underestimated radiological
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fibrosis patterns in the RA group not diagnosed with
ILD [1]. In addition, there was a profound variation in
length of disease (1.4–33 years) and treatment strategy
in the RA category.
In general, it is estimated that 20% of RA patients
develop ILD. In the present study 56% of RA pa-
tients and 100% of the RA-ILD patients had reduced
DLCOc. The RA-ILD group, was composed of sev-
eral different ILD subtypes (NSIP 40%, UIP 10%, BO
30% and HP 20%). A study with the power to
analyze fibrocyte levels and activation in the differ-
ent RA-ILD subgroups, could potentially provide a
deeper understanding of the role of fibrocytes and
the difference in pathogenesis of these RA-ILD
subtypes.
This result is consistent with a recent and major
retrospective study on 550 RA patients, which found
that 43% of these patients had or were about to de-
velop RA-ILD [35]. In the study, the RA-ILD diag-
nosis was based on HRCT, and patients with RA-
ILD had a significantly and expected DLCO reduc-
tion compared to other RA patients. Not all RA pa-
tients develop RA-ILD, and to identify factors
protecting against development of lung fibrosis is
crucial. Especially the potential role of smoking,
linked to fibrocyte levels in the present study, and
anti-CCP positivity, which we did not find linked to
fibrocyte level, deserves further investigation. The
role of Methotrexate in treatment of RA-ILD is cur-
rently unclear and also deserves further study [1].
We found a trend toward lower levels of both circu-
lating and number of mature fibrocytes in Metho-
trexate treated versus untreated RA patients,
although not significant (p = 0.16 and p = 0.05
respectively).
We are currently conducting a larger prospective RA
study with newly diagnosed and untreated RA and long-
standing RA patients to further study the role of fibro-
cytes in RA-ILD.
Conclusions
We presented a fast and valid method for measuring
circulating fibrocytes using flow cytometry on lysed
peripheral blood. Further, we showed for the first
time, that the level of circulating fibrocytes correlated
with the number of mononuclear cells that differenti-
ated into mature fibrocytes in vitro. Reduced DLCOc
was correlated with high levels of circulating and ma-
ture fibrocytes in RA, which has not been reported
previously. In such, this study suggests that fibrocytes
may exhibit an important role in the pathogenesis of
RA-ILD, which requires further clarification in future
studies.
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